Stroke is the leading cause of adult long-term disability and the third leading cause of death in the U.S. An estimated 795,000 Americans and 1.1 million Europeans are affected by stroke annually. It is estimated that 5 million stroke survivors are living today in the U.S., of whom 20%, or one million individuals, are disabled. Stroke occurs when part of the brain is deprived of adequate oxygen. There are two kinds of strokes: ischemic and hemorrhagic. Ischemic stroke occurs when the blood supply to the brain is interrupted, usually by a blood clot. The majority (87%) of strokes are ischemic. Hemorrhagic stroke is caused by the bleeding of ruptured blood vessels in the brain. |
 |
During ischemic stroke, diminished blood supply initiates a series of events (called ischemic cascade) that results in damage to brain tissue and eventually death of brain tissue. Brain tissue death occurs in areas of no blood flow within minutes of stroke onset. Around such areas, there could be regions of reversible injured tissue, called the ischemic penumbra. The ischemic penumbra will finally die if no change in blood flow occurs, and hence saving the penumbra is the goal of acute stroke therapies. To date, intravenous tissue plasminogen activator (IV t-PA) is the only approved interventional treatment for acute ischemic stroke. It is focused on reperfusion, i.e. aiming to restore artery patency and brain perfusion in order to reduce the volume of cerebral infarction which thereby reduces functional deficits. However, there is a high risk in reperfusion after several hours have passed from stroke onset, as the chances of inducing a cerebral hemorrhage dramatically increase. As a result, use of this treatment is limited to 3-6 hours from stroke onset. In the US, only about 4% of ischemic stroke patients are treated with IV t-PA. An unmet need exists for developing additional therapies for the treatment of acute ischemic stroke at a wider therapeutic window as well as for an improvement in outcome during the rehabilitation phase. For more information about stroke see the Heart Disease and Stroke Statistics, 2009 update by the American Heart Associateion
|
|
March 3, 2010
ISC 2010 San Antonio, TX
BrainsGate attends the International Stroke Conference (ISC) 2010 in San Antonio, TX > full story
November 17, 2009
Investigational neurostimulation device aims to reduce stroke damage
Stroke researchers at the Methodist Neurological Institute in Houston are the only ones in Texas to offer a novel device that might extend the acute stroke treatment window from three hours to 24 (PhysOrg.com)
> full story
|